{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:34:35Z","timestamp":1793370875183,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["fertstertreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["F&S Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.xfre.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T22:21:51Z","timestamp":1720045311000},"page":"356-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The role of elagolix in ovulation suppression during controlled ovarian stimulation: a retrospective cohort study"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4832-2198","authenticated-orcid":false,"given":"David","family":"Soliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Naoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Zaied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xfre.2024.06.006_bib1","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xfre.2024.06.006_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1749-6632.1991.tb37919.x","article-title":"GnRH analogues in ovarian stimulation","volume":"626","author":"Gordon","year":"1991","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.xfre.2024.06.006_bib3","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1210\/clinem\/dgz086","article-title":"Elagolix suppresses ovulation in a dose-dependent manner: results from a 3-month, randomized study in ovulatory women","volume":"105","author":"Archer","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfre.2024.06.006_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s40267-019-00606-y","article-title":"Elagolix in endometriosis-related pain: a profile of its use as approved in the USA","volume":"35","author":"Lyseng-Williamson","year":"2019","journal-title":"Drugs Ther Perspect"},{"key":"10.1016\/j.xfre.2024.06.006_bib5","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40265-018-0977-4","article-title":"Elagolix: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.xfre.2024.06.006_bib6","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1210\/jc.2016-3845","article-title":"Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women","volume":"102","author":"Ng","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfre.2024.06.006_bib7","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMcp1000274","article-title":"Clinical practice. Endometriosis","volume":"362","author":"Giudice","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xfre.2024.06.006_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xfre.2024.06.006_bib9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1210\/jc.2008-1695","article-title":"Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix","volume":"94","author":"Struthers","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfre.2024.06.006_bib10","first-page":"179","article-title":"The role of elagolix in the suppression of ovulation in donor oocyte cycles","volume":"4","author":"Boniface","year":"2023","journal-title":"F S Rep"},{"key":"10.1016\/j.xfre.2024.06.006_bib11","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.fertnstert.2023.08.068","article-title":"Oral GnRH antagonist (elagolix) could represent a less invasive and more cost-effective alternative to the injectable GnRH antagonist for ovulation suppression in in\u00a0vitro fertilization","volume":"120","author":"Mouanness","year":"2023","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2024.06.006_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bpobgyn.2019.01.004","article-title":"Embryo transfer techniques","volume":"59","author":"Saravelos","year":"2019","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.xfre.2024.06.006_bib13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.fertnstert.2019.12.034","article-title":"Trophectoderm biopsy protocols can affect clinical outcomes: time to focus on the blastocyst biopsy technique","volume":"113","author":"Rubino","year":"2020","journal-title":"Fertil Steril"},{"issue":"2 Suppl","key":"10.1016\/j.xfre.2024.06.006_bib14","first-page":"65","article-title":"Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix","volume":"4","author":"Chwalisz","year":"2023","journal-title":"F S Rep"},{"issue":"2 Suppl","key":"10.1016\/j.xfre.2024.06.006_bib15","first-page":"56","article-title":"Ganirelix and the prevention of premature luteinizing hormone surges","volume":"4","author":"Mannaerts","year":"2023","journal-title":"F S Rep"},{"key":"10.1016\/j.xfre.2024.06.006_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.fertnstert.2018.11.024","article-title":"At last, an orally active gonadotropin-releasing hormone antagonist","volume":"111","author":"Paulson","year":"2019","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2024.06.006_bib17","first-page":"647","article-title":"Does high estrogen level negatively affect pregnancy success in frozen embryo transfer?","volume":"18","author":"\u00d6zdemir","year":"2020","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.xfre.2024.06.006_bib19","author":"Pharmacy"}],"container-title":["F&S Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666334124000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666334124000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T19:09:09Z","timestamp":1734548949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666334124000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2666334124000771"],"URL":"https:\/\/doi.org\/10.1016\/j.xfre.2024.06.006","relation":{},"ISSN":["2666-3341"],"issn-type":[{"value":"2666-3341","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of elagolix in ovulation suppression during controlled ovarian stimulation: a retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"F&S Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xfre.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}